A Phase 4 interventional study of Human Regular U-500 Insulin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 39 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-22.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 4, and was the 39th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 87th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 in phase 4, and was the 97th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
Drug: Human Regular U-500 Insulin
U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
Drug: Human Regular U-500 Insulin
Also known as: LY041001, Humulin R, U-500R
Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, Week 24
Percentage of Participants Achieving HbA1c of ≤6.5%, <7.0%, <7.5%, and <8.0% at Week 24
The percentage of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.
Time frame: Week 24
30-Day Adjusted Rate of Hypoglycemic Events
Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through Week 24
Change From Baseline to Week 24 in Body Weight
LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin
Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin
Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels
LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.
Time frame: Baseline, Week 24
Time to Reach HbA1c Target Values
The cumulative number of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.
Time frame: Baseline through 6, 12, 18, and 24 weeks.
Percentage of Participants With Hypoglycemic Events
Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through Week 24
Change From Baseline to Week 24 in Number of Insulin Injections
The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.
Time frame: Baseline, Week 24
Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)
The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg
Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or \>2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (\>300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.
Time frame: Baseline, Week 24
| Milestone | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Started | 162 | 163 |
| Received at least 1 dose of study drug | 162 | 161 |
| Completed | 132 | 128 |
| Not completed | 30 | 35 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Physician decision | 5 | 1 |
| Withdrew: Protocol violation | 14 | 13 |
| Withdrew: Sponsor decision | 0 | 2 |
| Withdrew: Withdrawal by subject | 6 | 11 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.
| percentage of HbA1c | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c) | -1.12 ± 0.08 | -1.22 ± 0.08 |
The percentage of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.
| percentage of participants | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| HbA1c ≤6.5% (n=159, 161) | 20.13 | 23.60 |
| HbA1c <7.0% (n=158, 159) | 42.41 | 41.51 |
| HbA1c <7.5% (n=148, 143) | 64.19 | 61.54 |
| HbA1c <8.0% (n=120, 123) | 77.50 | 77.24 |
Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per 30 days | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Severe HE | 0.004 ± 0.028 | 0.009 ± 0.053 |
| Documented Symptomatic HE | 3.343 ± 3.174 | 3.885 ± 3.448 |
| Documented Symptomatic Nocturnal HE | 1.013 ± 1.438 | 1.299 ± 1.540 |
| Asymptomatic HE | 1.340 ± 3.215 | 1.028 ± 2.231 |
LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.
| kilograms (kg) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Change From Baseline to Week 24 in Body Weight | 5.44 ± 0.41 | 4.88 ± 0.41 |
Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.
| units | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin | 55.19 ± 10.16 | 51.39 ± 10.24 |
Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.
| units per kilogram (units/kg) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin | 0.32 ± 0.08 | 0.32 ± 0.08 |
LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.
| milligrams per deciliter (mg/dL) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels | -6.66 ± 5.64 | -8.86 ± 5.72 |
The cumulative number of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.
| participants | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| HbA1c ≤6.5%, Week 6 (n=154, 155) | 1 | 6 |
| HbA1c ≤6.5%, Week 12 (n=145, 151) | 15 | 15 |
| HbA1c ≤6.5%, Week 18 (n=140, 145) | 24 | 27 |
| HbA1c ≤6.5%, Week 24 (n=76, 65) | 28 | 37 |
| HbA1c <7.0%, Week 6 (n=154, 153) | 14 | 10 |
| HbA1c <7.0%, Week 12 (n=148, 149) | 31 | 36 |
| HbA1c <7.0%, Week 18 (n=144, 145) | 52 | 55 |
| HbA1c <7.0%, Week 24 (n=53, 52) | 60 | 65 |
| HbA1c <7.5%, Week 6 (n=144, 137) | 30 | 20 |
| HbA1c <7.5%, Week 12 (n=140, 134) | 59 | 59 |
| HbA1c <7.5%, Week 18 (n=136, 132) | 81 | 78 |
| HbA1c <7.5%, Week 24 (n=34, 31) | 90 | 87 |
| HbA1c <8.0%, Week 6 (n=117, 117) | 32 | 34 |
| HbA1c <8.0%, Week 12 (n=114, 115) | 66 | 72 |
| HbA1c <8.0%, Week 18 (n=111, 113) | 85 | 86 |
| HbA1c <8.0%, Week 24 (n=20, 19) | 89 | 95 |
Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Severe HE | 1.85 | 3.73 |
| Documented Symptomatic HE | 91.98 | 90.06 |
| Documented Symptomatic Nocturnal HE | 77.78 | 80.75 |
| Asymptomatic HE | 64.20 | 66.46 |
The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.
| injections per day | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Baseline | 4.765 ± 1.234 | 4.783 ± 1.307 |
| Week 24 | 3.000 ± 0.000 | 2.000 ± 0.000 |
The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.
| mg/dL | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Pre-morning Meal (n=150, 149) | -24.10 ± 3.96 | -29.19 ± 3.91 |
| 2 Hours After Morning Meal (n=146, 133) | -21.68 ± 4.29 | -31.32 ± 4.29 |
| Pre-midday Meal (n=150, 149) | -23.54 ± 4.17 | -32.26 ± 4.11 |
| 2 Hours After Midday Meal (n=143, 133) | -24.31 ± 4.50 | -22.53 ± 4.49 |
| Pre-evening Meal (n=150, 149) | -34.17 ± 3.93 | -32.96 ± 3.85 |
| 2 Hours After Evening Meal (n=147, 142) | -40.56 ± 4.13 | -38.36 ± 4.11 |
| 3 AM (n=147, 140) | -36.77 ± 4.34 | -47.82 ± 4.29 |
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.
| percentage of HbA1c | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Baseline TDD ≤2.0 units/kg (n=50, 46) | -0.99 ± 0.14 | -1.32 ± 0.15 |
| Baseline TDD >2.0 units/kg (n=112, 115) | -1.19 ± 0.10 | -1.18 ± 0.10 |
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per 30 days | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Severe HE, TDD ≤2 units/kg, Baseline (n=50, 46) | 0 ± 0 | 0 ± 0 |
| Severe HE, TDD ≤2 units/kg, Week 24 (n=50, 46) | 0.004 ± 0.025 | 0 ± 0 |
| Severe HE, TDD >2 units/kg, Baseline (n=112, 115) | 0 ± 0 | 0 ± 0 |
| Severe HE, TDD >2 units/kg, Week 24 (n=112, 115) | 0.004 ± 0.029 | 0.013 ± 0.062 |
| DS HE, TDD ≤2 units/kg, Baseline (n=50, 46) | 1.958 ± 4.808 | 1.454 ± 3.251 |
| DS HE, TDD ≤2 units/kg, Week 24 (n=50, 46)) | 2.356 ± 2.352 | 3.131 ± 3.204 |
| DS HE, TDD >2 units/kg, Baseline (n=112, 115) | 2.037 ± 4.382 | 1.730 ± 3.180 |
| DS HE, TDD >2 units/kg, Week 24 (n=112, 115) | 3.784 ± 3.397 | 4.186 ± 3.509 |
| Noc. HE, TDD ≤2 units/kg, Baseline (n=50, 46) | 1.066 ± 2.045 | 0.711 ± 1.965 |
| Noc. HE, TDD ≤2 units/kg, Week 24 (n=50, 46) | 1.105 ± 1.153 | 1.282 ± 1.431 |
| Noc. HE, TDD >2 units/kg, Baseline (n=112, 115) | 0.792 ± 2.465 | 0.585 ± 1.445 |
| Noc. HE, TDD >2 units/kg, Week 24 (n=112, 115) | 1.522 ± 2.018 | 1.753 ± 1.934 |
Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or \>2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (\>300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.
| percentage of participants | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Baseline TDD≤2.0 U/kg, Baseline risk (n=50, 46) | 56.00 | 39.13 |
| Baseline TDD ≤2.0 U/kg, Week 24 risk (n=50, 46) | 94.00 | 86.96 |
| Baseline TDD >2.0 U/kg, Baseline risk (n=112, 115) | 47.32 | 51.30 |
| Baseline TDD >2.0 U/kg, Week 24 risk (n=112, 115) | 96.43 | 97.39 |
Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.
| kg | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| Baseline TDD insulin ≤2.0 units/kg (n=50, 46) | 6.11 ± 0.88 | 6.09 ± 0.93 |
| Baseline TDD insulin >2.0 units/kg (n=112, 115) | 5.08 ± 0.44 | 4.40 ± 0.43 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Human Regular U-500 Insulin TID | — | 28/162 (17.3%) | 80/162 (49.4%) |
| Human Regular U-500 Insulin BID | — | 27/163 (16.6%) | 94/163 (57.7%) |
| Event | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/162 | 6/163 |
| Acute myocardial infarctionCardiac disorders | 3/162 | 1/163 |
| Cardiac failure congestiveCardiac disorders | 1/162 | 3/163 |
| PneumoniaInfections and infestations | 1/162 | 3/163 |
| Chest painGeneral disorders | 2/162 | 2/163 |
| CellulitisInfections and infestations | 2/162 | 1/163 |
| Renal failure acuteRenal and urinary disorders | 0/162 | 2/163 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/162 | 2/163 |
| Atrial fibrillationCardiac disorders | 1/162 | 0/163 |
| Coronary artery diseaseCardiac disorders | 1/162 | 1/163 |
| Event | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/162 | 17/163 |
| Upper respiratory tract infectionInfections and infestations | 13/162 | 9/163 |
| HeadacheNervous system disorders | 13/162 | 6/163 |
| VomitingGastrointestinal disorders | 4/162 | 11/163 |
| DiarrhoeaGastrointestinal disorders | 6/162 | 10/163 |
| Oedema peripheralGeneral disorders | 6/162 | 10/163 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/162 | 10/163 |
| BronchitisInfections and infestations | 9/162 | 5/163 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/162 | 7/163 |
| NauseaGastrointestinal disorders | 4/162 | 9/163 |
All randomized participants.
| Age, Continuous(years) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID | Total |
|---|---|---|---|
| Mean | 55.31 ± 10.51 | 55.50 ± 9.03 | 55.41 ± 9.78 |
| Sex: Female, Male(Participants) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID | Total |
|---|---|---|---|
| Female | 79 | 74 | 153 |
| Male | 83 | 89 | 172 |
| Ethnicity (NIH/OMB)(Participants) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 30 | 62 |
| Not Hispanic or Latino | 130 | 133 | 263 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 21 | 19 | 40 |
| White | 133 | 133 | 266 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Human Regular U-500 Insulin TID | Human Regular U-500 Insulin BID | Total |
|---|---|---|---|
| United States | 146 | 149 | 295 |
| Puerto Rico | 16 | 14 | 30 |
The record gives a start of Feb 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human